Clinical Trials Logo

Filter by:
NCT ID: NCT06347198 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Start date: April 10, 2024
Phase: Early Phase 1
Study type: Interventional

This is a single-center exploratory clinical study to explore the efficacy and safety of Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer.

NCT ID: NCT06346912 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Start date: May 30, 2024
Phase: Early Phase 1
Study type: Interventional

Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

NCT ID: NCT06346821 Recruiting - Clinical trials for Glioblastoma Multiforme

Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data

Start date: July 4, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about the effectiveness of Optune® (Tumor Treating Fields) in newly diagnosed glioblastoma (GBM) in China. The main question it aims to answer are: - The efficacy of Optune® as an concomitant/adjuvant to radiation therapy (RT) and temozolomide (TMZ) alone in the treatment of newly diagnosed GBM patients. - The effectiveness of Optune® given concomitantly with RT and TMZ in newly diagnosed GBM patients, compared to RT and TMZ alone. Participants will: - Receive or not receive TTFields. - Concomitantly or adjuvantly receive TTFields.

NCT ID: NCT06346613 Recruiting - Critical Illness Clinical Trials

Prevalence and Affecting Factors of Sleep and Circadian Rhythm Disorders in ICU

Start date: March 7, 2024
Phase:
Study type: Observational

Most ICU patients experience sleep and circadian disruption (SCD), which causes a profound negative impact on patients, such as prolonged mechanical ventilation, glucose intolerance, and the occurrence of delirium. In order to better promote the alignment of circadian rhythm in ICU patients, this project will explore the prevalence of SCD and a series of influencing factors contributing to SCD in ICU patients, to help construct targeted intervention programs in the future.

NCT ID: NCT06346600 Recruiting - Clinical trials for Neovascular (Wet) Age-related Macular Degeneration

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Start date: April 2, 2024
Phase:
Study type: Observational

This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.

NCT ID: NCT06346392 Recruiting - Gastric Cancer Clinical Trials

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Start date: March 4, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

NCT ID: NCT06346379 Recruiting - Rehabilitation Clinical Trials

The Effect of Baduanjin on Physical Fitness and Bone Density in Maintenance Hemodialysis Patients

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to examine the effect of 12-month Baduanjin exercise on physical fitness and bone density in maintenance hemodialysis (MHD) patients. 50 MHD patients aged 18-75 will included in this study and randomly divided into two groups (intervention group and control group). The intervention group will be led by a professional person and underwent Baduanjin exercise three times a week before hemodialysis. The control group maintained routine treatment and daily activities.

NCT ID: NCT06346093 Recruiting - Clinical trials for Advanced Gastric Cancer

Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer

Start date: April 2, 2024
Phase: N/A
Study type: Interventional

This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD-L1 therapy in the advanced gastric cancer.

NCT ID: NCT06346041 Recruiting - Neoplasms Clinical Trials

Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

Start date: April 12, 2024
Phase: Early Phase 1
Study type: Interventional

This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-SAFETM in patients with advanced solid tumors.

NCT ID: NCT06345898 Recruiting - Clinical trials for X Linked Retinoschisis

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

Start date: November 17, 2023
Phase: Early Phase 1
Study type: Interventional

This trial is to evaluate the safety and efficacy of JWK002 treatment of X-linked retinoschisis(XLRS). This study will enroll subjects aged 5-18 years old to receive a sub-retinal injection of JWK002.